Viewing StudyNCT00000870



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00000870
Status: COMPLETED
Last Update Posted: 2012-05-21
First Post: 1999-11-02

Brief Title: A Phase II Study of Intermittent Recombinant Human Interleukin-2 rhIL-2 by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy HAART Compared to HAART Alone
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institute of Allergy and Infectious Diseases NIAID

Conditions & Keywords Data

Conditions:
Name
HIV Infections
Keywords:
Name View
Anti-HIV Agents View
Recombinant Proteins View
Infusions Intravenous View
Injections Intravenous View
Injections Subcutaneous View
Interleukin-2 View
Drug Administration Schedule View
CD4 Lymphocyte Count View
Quality of Life View